These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26307134)

  • 1. Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
    Zhang T; Armstrong AJ
    Clin Cancer Res; 2015 Oct; 21(20):4505-7. PubMed ID: 26307134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
    Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
    Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
    Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
    Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
    Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
    Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
    Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
    Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
    Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
    Wang M; Ma X; Wang J; Wang L; Wang Y
    Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch signaling, gamma-secretase inhibitors, and cancer therapy.
    Shih IeM; Wang TL
    Cancer Res; 2007 Mar; 67(5):1879-82. PubMed ID: 17332312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
    Pond GR; Berry WR; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Clin Genitourin Cancer; 2012 Dec; 10(4):239-45. PubMed ID: 23000202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for metastatic castration-sensitive prostate cancer.
    Parimi S; Chi KN
    Int J Urol; 2016 Sep; 23(9):726-33. PubMed ID: 27345496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
    Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
    Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
    Lo Nigro C; Maffi M; Fischel JL; Formento P; Milano G; Merlano M
    BJU Int; 2008 Aug; 102(5):622-7. PubMed ID: 18494832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
    Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
    Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.